PMID- 15472895
OWN - NLM
STAT- MEDLINE
DCOM- 20050308
LR  - 20071114
IS  - 1045-2257 (Print)
IS  - 1045-2257 (Linking)
VI  - 42
IP  - 1
DP  - 2005 Jan
TI  - Chromosomal imbalances detected by array comparative genomic hybridization in 
      human oligodendrogliomas and mixed oligoastrocytomas.
PG  - 68-77
AB  - Loss of heterozygosity and fluorescence in situ hybridization (FISH) studies have 
      shown that deletions of 1p and 19q are highly prevalent in oligodendroglioma. 
      However, these tumors have not been comprehensively screened for other 
      alterations in chromosomal dosage. In this study, we used array-based comparative 
      genomic hybridization (CGHa) of mapped BAC DNA to screen for such alterations in 
      31 oligodendrogliomas (20 grade II, 9 grade III, and 2 grade IV) and 4 mixed 
      oligoastrocytomas (1 grade I, 1 grade II, and 2 grade IV). The most frequent 
      aberrations were loss of 1p (17 cases; 49%) and 19q (15 cases; 43%) and combined 
      loss of 1p/19q (13 cases; 37%). In addition, deletion of 4q, 5p, 9p, 10q, 11p, 
      and 13q was observed in 10, 4, 8, 4, 4, and 13 cases, respectively; loss of whole 
      chromosomes 4, 9, and 13 in 4, 1, and 7 cases, respectively; gain of 7p, 8q, 10p, 
      and 11q in 6, 6, 5, and 10 cases, respectively, and gain of whole chromosomes 7 
      and 11 in 2 patients each. Minimally altered regions detected by CGHa involved 
      chromosome bands 1p36.32, 4q33, 5p15, 8q24, 11p15, and 19q13.3. Univariate 
      analysis of all 35 cases suggested that combined deletion of 1p and 19q is 
      associated with better survival (P = 0.03). In addition, 8q gain in the 
      oligodendrogliomas was strongly associated with poor outcome (P = 0.002). Also 
      associated with poor disease outcome were alterations that had low prevalence in 
      the pure oligodendrogliomas, including loss of 3q, 9q, and 12q and gain of 1p, 
      8p, and 10q. In summary, in oligodendrogliomas, CGHa was able to detect novel 
      small alterations in chromosomal dosage that had not been previously detected by 
      other methods. In addition, our findings support the hypotheses that 
      oligodendroglioma can be classified into several groups by CGHa analysis and that 
      specific alterations in genetic dosage may have biologic or clinical 
      significance.
FAU - Kitange, Gaspar
AU  - Kitange G
AD  - Division of Laboratory Genetics, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Misra, Anjan
AU  - Misra A
FAU - Law, Mark
AU  - Law M
FAU - Passe, Sandra
AU  - Passe S
FAU - Kollmeyer, Thomas M
AU  - Kollmeyer TM
FAU - Maurer, Matthew
AU  - Maurer M
FAU - Ballman, Karla
AU  - Ballman K
FAU - Feuerstein, Burt G
AU  - Feuerstein BG
FAU - Jenkins, Robert B
AU  - Jenkins RB
LA  - eng
GR  - CA85799/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Genes Chromosomes Cancer
JT  - Genes, chromosomes & cancer
JID - 9007329
SB  - IM
MH  - Adult
MH  - Astrocytoma/*genetics/pathology
MH  - Brain Neoplasms/*genetics/pathology
MH  - Child
MH  - Chromosome Mapping
MH  - Chromosomes, Human, Pair 1/genetics
MH  - Chromosomes, Human, Pair 19/genetics
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nucleic Acid Hybridization/*genetics
MH  - Oligodendroglioma/*genetics/pathology
MH  - Oligonucleotide Array Sequence Analysis
EDAT- 2004/10/09 09:00
MHDA- 2005/03/09 09:00
CRDT- 2004/10/09 09:00
PHST- 2004/10/09 09:00 [pubmed]
PHST- 2005/03/09 09:00 [medline]
PHST- 2004/10/09 09:00 [entrez]
AID - 10.1002/gcc.20108 [doi]
PST - ppublish
SO  - Genes Chromosomes Cancer. 2005 Jan;42(1):68-77. doi: 10.1002/gcc.20108.